Additional drugmakers flag risks of working with WuXi amid heightened US scrutiny

More drug companies are disclosing the potential for clinical trial delays and drug shortages if the US government blacklists a family of WuXi companies used across the biopharma industry.

The disclosures come from companies large and small, including Merck, Cabaletta Bio and Kyverna Therapeutics. Through securities filings, Endpoints News identified…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks